Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461818 | 1.00 | GAA (0.37) | GAAMAPTCA1CA2CA9 | |
| SCHEMBL19762452 | 0.82 | MAPT (0.40) | GAAMAPTCA1CA2CA9 | |
| SCHEMBL29127438 | 0.78 | SMN1; SMN2 (0.38) | GAAMAPTKDM4EMBOAT4 | |
| SCHEMBL25292365 | 0.77 | GAA (0.40) | GAAMAPTCA1CA2CA9 | |
| SCHEMBL27385578 | 0.77 | TDP1 (0.39) | GAAKMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL19202623 | 0.77 | CYP3A4 (0.40) | GAAMAPTKMT2AKDM4ELMNA | |
| SCHEMBL11985887 | 0.77 | LMNA (0.35) | KMT2ALMNAALDH1A1HPGDAPOBEC3G | |
| SCHEMBL31378257 | 0.74 | MAPT (0.37) | GAAMAPTCA1CA2CA9 | |
| SCHEMBL29257731 | 0.74 | LMNA (0.41) | KMT2AKDM4ELMNAALDH1A1NR1I2 | |
| SCHEMBL22715659 | 0.71 | KMT2A (0.36) | GAAMAPTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| WO-2018007249-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-01-11 | — | — | WO | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| WO-2017220431-A1 | FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017201683-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205193-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| CN-107074787-A | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2017-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | GAA 2873/4885MAPT 3414/4885CA1 4082/4885 |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | GAA 3459/4885MAPT 3898/4885CA1 4078/4885 |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | GAA 1864/4885MAPT 3757/4885CA1 2333/4885 |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | GAA 322/4885MAPT 246/4885CA1 3545/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | GAA 322/4885MAPT 246/4885CA1 3545/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | GAA 192/4885MAPT 1555/4885CA1 1962/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | GAA 1225/4885MAPT 2737/4885CA1 4707/4885 |
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RBM17, SF3B5, SF3A2 | GAA 1663/4885MAPT 4519/4885CA1 4863/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | GAA 11/4885MAPT 15/4885CA1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.